• Please log in or register to access this feature.

ORIGINAL PAPER

You have free access to this content

Central Hemodynamics in Prehypertension: Effect of the β-Adrenergic Antagonist Nebivolol

  1. Jason T. Davis MD,
  2. Dalal N. Pasha BS,
  3. Srikrishna Khandrika PhD,
  4. Maple M. Fung MD,
  5. Milos Milic PhD,
  6. Daniel T. O’Connor MD

Article first published online: 26 OCT 2012

DOI: 10.1111/jch.12031

Issue

The Journal of Clinical Hypertension

The Journal of Clinical Hypertension

Volume 15, Issue 1, pages 69–74, January 2013

Additional Information

How to Cite

Davis, J. T., Pasha, D. N., Khandrika, S., Fung, M. M., Milic, M. and O’Connor, D. T. (2013), Central Hemodynamics in Prehypertension: Effect of the β-Adrenergic Antagonist Nebivolol. The Journal of Clinical Hypertension, 15: 69–74. doi: 10.1111/jch.12031

Author Information

  1. From the Department of Medicine, VA San Diego Healthcare System and the University of California, San Diego, CA

*Jason T. Davis, Department of Medicine (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093-0838 E-mail:jasontdavis18@gmail.com

Publication History

  1. Issue published online: 3 JAN 2013
  2. Article first published online: 26 OCT 2012
  3. Manuscript received: April 14, 2012; revised: September 6, 2012; accepted: September 10, 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (87K)

References

  • 1
    Chobanian AV, Bakris GL, Black HR, et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA.2003;289:2560–2572.
  • 2
    Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit.2005;11:CR403–409.
  • 3
    Ishikawa Y, Ishikawa J, Ishikawa S, et al.Prehypertension and the risk for cardiovascular disease in the Japanese general population: the Jichi Medical School Cohort Study. J Hypertens.2010;28:1630–1637.
  • 4
    Drukteinis JS, Roman MJ, Fabsitz RR, et al.Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation.2007;115:221–227.
  • 5
    Julius S, Nesbitt SD, Egan BM, et al.Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med.2006;354:1685–1697.
  • 6
    Vollmer WM, Sacks FM, Ard J, et al.Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med.2001;135:1019–1028.
  • 7
    Davis JT, Rao F, Naqshbandi D, et al.Autonomic and hemodynamic origins of pre-hypertension: central role of heredity. J Am Coll Cardiol.2012;59:2206–2216.
  • 8
    Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol.2010;55:1318–1327.
  • 9
    Song BG, Park JB, Cho SJ, et al.Pulse wave velocity is more closely associated with cardiovascular risk than augmentation index in the relatively low-risk population. Heart Vessels.2009;24:413–418.
  • 10
    Roman MJ, Devereux RB, Kizer JR, et al.High central pulse pressure is independently associated with adverse cardiovascular outcome: the Strong Heart Study. J Am Coll Cardiol.2009;54:1730–1734.
  • 11
    Gedikli O, Kiris A, Ozturk S, et al.Effects of prehypertension on arterial stiffness and wave reflections. Clin Exp Hypertens.2010;32:84–89.
  • 12
    Kamp O, Metra M, Bugatti S, et al.Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs.2010;70:41–56.
  • 13
    Chio SS, Tsai JJ, Hsu YM, et al.Development and validation of a noninvasive method to estimate cardiac output using cuff sphygmomanometry. Clin Cardiol.2007;30:615–620.
    Direct Link:
  • 14
    Brinton TJ, Cotter B, Kailasam MT, et al.Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol.1997;80:323–330.
  • 15
    Fung MM, Rao F, Poddar S, et al.Early inflammatory and metabolic changes in association with AGTR1 polymorphisms in prehypertensive subjects. Am J Hypertens.2011;24:225–233.
  • 16
    Nambiar S, Viswanathan S, Zachariah B, et al.Oxidative stress in prehypertension: rationale for antioxidant clinical trials. Angiology.2009;60:221–234.
  • 17
    Kampus P, Serg M, Kals J, et al.Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension.2011;57:1122–1128.
  • 18
    Chirinos JA, Zambrano JP, Chakko S, et al.Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol.2005;96:645–648.
  • 19
    Williams B, Lacy PS, Thom SM, et al.Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation.2006;113:1213–1225.
  • 20
    Wang KL, Cheng HM, Chuang SY, et al.Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?J Hypertens.2009;27:461–467.
  • 21
    Elliott WJ, Childers WK. Should beta blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?Curr Cardiol Rep.2011;13:507–516.
  • 22
    Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta.1999;1411:273–289.
  • 23
    Gamboa A, Okamoto LE, Diedrich A, et al.Sympathetic activation and nitric oxide function in early hypertension. Am J Physiol Heart Circ Physiol.2012;302:H1438–1443.
  • 24
    Gamboa A, Shibao C, Diedrich A, et al.Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension.2007;49:170–177.
  • 25
    Forte P, Copland M, Smith LM, et al.Basal nitric oxide synthesis in essential hypertension. Lancet.1997;349:837–842.
  • 26
    Owlya R, Vollenweider L, Trueb L, et al.Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation.1997;96:3897–3903.
  • 27
    Wu TL, Chang PY, Tsao KC, et al.A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease. J Clin Lab Anal.2007;21:367–371.
    Direct Link:
  • 28
    Morrow JD, Frei B, Longmire AW, et al.Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med.1995;332:1198–1203.
  • 29
    Collins C, Tzima E. Hemodynamic forces in endothelial dysfunction and vascular aging. Exp Gerontol.2011;46:185–188.
  • 30
    Vita JA. Nitric oxide and vascular reactivity in African American patients with hypertension. J Card Fail.2003;9(5 Suppl Nitric Oxide):S199–204; discussion S205-199.
  • 31
    Tillin T, Chambers J, Malik I, et al.Measurement of pulse wave velocity: site matters. J Hypertens.2007;25:383–389.
  • 32
    Figueroa A, Sanchez-Gonzalez MA, Perkins-Veazie PM, Arjmandi BH. Effects of watermelon supplementation on aortic blood pressure and wave reflection in individuals with prehypertension: a pilot study. Am J Hypertens.2011;24:40–44.
  • 33
    Celik T, Iyisoy A, Acikel C, et al.The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension. Blood Press Monit.2008;13:169–176.
  • 34
    Soanker R, Naidu MU, Raju SB, et al.Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol.2012;44:407–411.
  • 35
    Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens.2008;21:663–667.
  • 36
    Mitchell GF, Parise H, Benjamin EJ, et al.Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension.2004;43:1239–1245.
  • 37
    Collaboration” TRVfAS. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values.’Eur Heart J.2010;31:2338–2350.
  • 38
    Wilkinson IB, MacCallum H, Flint L, et al.The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol.2000;525(Pt 1):263–270.
    Direct Link:
  • 39
    Smulyan H, Vardan S, Griffiths A, Gribbin B. Forearm arterial distensibility in systolic hypertension. J Am Coll Cardiol.1984;3(2 Pt 1):387–393.
  • 40
    O’Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension.1990;15:339–347.
  • 41
    Vyas M, Izzo JL Jr, Lacourciere Y, et al.Augmentation index and central aortic stiffness in middle-aged to elderly individuals. Am J Hypertens.2007;20:642–647.
  • 42
    Wilkinson IB, MacCallum H, Hupperetz PC, et al.Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol.2001;530(Pt 3):541–550.
    Direct Link:
  • 43
    Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension.2001;37:1429–1433.
View Full Article with Supporting Information (HTML) Get PDF (87K)